Bank Of America Corp Galecto, Inc. Transaction History

Bank Of America Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.47 - $0.76 $76 - $123	162 Added 0.53%	30,563 $14,000
Q4 2023 Feb 14, 2024	SELL	$0.52 - $0.78 $9,210 - $13,816	-17,713 Reduced 36.81%	30,401 $21,000
Q2 2023 Aug 14, 2023	SELL	$1.68 - $2.84 $6,988 - $11,814	-4,160 Reduced 7.96%	48,114 $121,000
Q1 2023 May 12, 2023	BUY	$1.21 - $2.86 $2,860 - $6,761	2,364 Added 4.74%	52,274 $104,000
Q4 2022 Feb 10, 2023	BUY	$1.06 - $58.5 $3,256 - $179,712	3,072 Added 6.56%	49,910 $57,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $60.0 $15,623 - $589,560	9,826 Added 26.55%	46,838 $89,000
Q2 2022 Aug 12, 2022	BUY	$1.22 - $2.74 $852 - $1,915	699 Added 1.92%	37,012 $64,000
Q1 2022 May 16, 2022	SELL	$1.72 - $3.31 $2,853 - $5,491	-1,659 Reduced 4.37%	36,313 $80,000
Q4 2021 Feb 08, 2022	BUY	$2.3 - $3.58 $1,161 - $1,807	505 Added 1.35%	37,972 $115,000
Q3 2021 Nov 15, 2021	BUY	$3.59 - $5.0 $7,097 - $9,885	1,977 Added 5.57%	37,467 $135,000
Q2 2021 Sep 13, 2021	BUY	$4.63 - $8.0 $164,318 - $283,920	35,490 New	35,490 $180,000

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $120M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.